Healthcare provider profile · identity verified

Sonja W. Tang, MD

Internal Medicine · FONTANA, CA · NPI 1710046321

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Losartan Potassium	Losartan Potassium	183	78
Amlodipine Besylate	Amlodipine Besylate	132	53
Atorvastatin Calcium	Atorvastatin Calcium	130	61
Levothyroxine Sodium	Levothyroxine Sodium	128	49
Atenolol	Atenolol	113	42
Furosemide	Furosemide	99	44
Lisinopril	Lisinopril	95	41
Gabapentin	Gabapentin	90	29
Potassium Chloride	Potassium Chloride	89	38
Albuterol Sulfate Hfa	Albuterol Sulfate	81	52
Alvesco	Ciclesonide	80	47
Ozempic	Semaglutide	77	suppressed
Omeprazole	Omeprazole	74	37
Metoprolol Tartrate	Metoprolol Tartrate	71	33
Terazosin Hcl	Terazosin Hcl	70	27
Simvastatin	Simvastatin	58	29
Rosuvastatin Calcium	Rosuvastatin Calcium	55	25
Trazodone Hcl	Trazodone Hcl	54	19
Alendronate Sodium	Alendronate Sodium	53	22
Famotidine	Famotidine	50	28
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	48	21
Pantoprazole Sodium	Pantoprazole Sodium	44	19
Hydrochlorothiazide	Hydrochlorothiazide	43	21
Wixela Inhub	Fluticasone Propion/Salmeterol	40	19
Metformin Hcl	Metformin Hcl	39	19
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	39	13
Sertraline Hcl	Sertraline Hcl	38	15
Allopurinol	Allopurinol	37	16
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	33	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	33	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	33	13
Duloxetine Hcl	Duloxetine Hcl	32	12
Mupirocin	Mupirocin	32	20
Nortriptyline Hcl	Nortriptyline Hcl	29	suppressed
Acyclovir	Acyclovir	28	13
Methocarbamol	Methocarbamol	28	suppressed
Glipizide	Glipizide	27	13
Metformin Hcl Er	Metformin Hcl	27	11
Azithromycin	Azithromycin	26	25
Meloxicam	Meloxicam	26	14
Ciprofloxacin Hcl	Ciprofloxacin Hcl	25	22
Spiriva Respimat	Tiotropium Bromide	25	suppressed
Citalopram Hbr	Citalopram Hydrobromide	24	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	23	23
Humalog	Insulin Lispro	23	suppressed
Estradiol	Estradiol	22	suppressed
Ezetimibe	Ezetimibe	22	suppressed
Humulin N	Insulin Nph Human Isophane	22	suppressed
Lidocaine	Lidocaine	22	14
Nystatin	Nystatin	22	suppressed
Nitroglycerin	Nitroglycerin	21	18
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	21	suppressed
Lovastatin	Lovastatin	20	suppressed
Azelastine Hcl	Azelastine Hcl	19	11
Victoza 3-Pak	Liraglutide	19	suppressed
Liraglutide	Liraglutide	18	suppressed
Prednisone	Prednisone	18	15
Bisoprolol Fumarate	Bisoprolol Fumarate	17	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	17	suppressed
Carvedilol	Carvedilol	16	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	16	suppressed
Pravastatin Sodium	Pravastatin Sodium	16	suppressed
Breyna	Budesonide/Formoterol Fumarate	15	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	15	suppressed
Hydralazine Hcl	Hydralazine Hcl	15	suppressed
Spironolactone	Spironolactone	15	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	15	suppressed
Cephalexin	Cephalexin	14	12
Combivent Respimat	Ipratropium/Albuterol Sulfate	14	suppressed
Eliquis	Apixaban	14	suppressed
Victoza 2-Pak	Liraglutide	14	suppressed
Bupropion Xl	Bupropion Hcl	13	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	13	11
Clonidine Hcl	Clonidine Hcl	12	suppressed
Clopidogrel	Clopidogrel Bisulfate	12	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	12	suppressed
Montelukast Sodium	Montelukast Sodium	12	suppressed
Risperidone	Risperidone	12	suppressed
Jardiance	Empagliflozin	11	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error